(Finance) – Rise for Tg Therapeutics,which changes hands in strong gains, surpassing the previous values by 6.25%.
The promotion from Evercore ISI contributes to assisting the actions. Research office experts raised the target price on the biopharmaceutical group’s stock to 16 dollars from 11 previously indicated and against 11.115 dollars.
Comparatively on a weekly basis, the trend of Tg Therapeutics, shows a more marked trend than the trendline NASDAQ 100. This demonstrates the greater propensity of investors to buy towards Tg Therapeutics, compared to the index.
The short-term technical framework of Tg Therapeutics, shows an upward acceleration of the curve with a target identified at 11.57 USD. Risk of a fall to 10.47 which will not affect the good health of the current trend but which represents a temporary correction. Expectations are for an extension of the uptrendline towards 12.66.